Stable TLR Agonist Formulation with Helper-Lipid Aluminum Adsorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing adjuvants like aluminum salts effectively boost antibody responses but fail to substantially augment cellular immunity, necessitating the development of formulations that can adsorb TLR7/8 and TLR4 agonists for enhanced immune response, particularly for diseases such as tuberculosis, HIV, and malaria.
Innovation Solution
A stable aqueous formulation comprising a TLR7/8 or TLR4 agonist combined with a helper lipid, which is adsorbed to an aluminum salt, forming a nanosuspension with particles sized at 400 nm or less, ensuring stability and enhanced adjuvant activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TLR7/8 agonists (such as imidazoquinolines) are used to augment cellular immunity, then cellular immune response is improved, but adsorption to aluminum oxyhydroxide is poor due to lack of structural compatibility
Solution Approach 1:
The patent introduces an intermediary substance (helper lipid or surfactant) that mediates between the TLR7/8 agonist and aluminum oxyhydroxide. The helper lipid forms a complex with the TLR agonist, creating a structure that can be adsorbed onto the aluminum salt surface, thus enabling attachment of molecules that would otherwise not bind to aluminum oxyhydroxide
Solution Approach 2:
The patent creates a composite adjuvant system consisting of multiple components: TLR agonist, helper lipid, and aluminum salt. This composite structure combines the immunostimulatory properties of the TLR agonist with the adsorption capabilities of aluminum oxyhydroxide, achieving both cellular immunity augmentation and stable formulation
2Reliability
If multiple immunostimulants are adsorbed to aluminum salts to enhance cellular immunity, then immune response is improved, but formulation complexity increases
Solution Approach 1:
The patent merges multiple functional components into a single integrated adjuvant system. The helper lipid serves multiple functions: it complexes with the TLR agonist, enables aluminum salt adsorption, and provides structural organization. This consolidation reduces formulation complexity while maintaining enhanced immune response
3Device complexity
If TLR agonists are formulated without helper lipid, then formulation is simpler, but stability and adjuvant activity are reduced
Solution Approach 1:
The helper lipid acts as an intermediary that stabilizes the TLR agonist formulation and enhances its adjuvant activity. It forms protective complexes with the agonist, prevents degradation, and facilitates proper interaction with immune cells, thereby improving reliability without excessive complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation stimulates both antibody and cellular immune responses, providing a stable adjuvant effect for up to one year at 2-8°C, suitable for vaccines against tuberculosis, influenza, cancer, and amebiasis, among others.
Implementation Method 1
aluminum oxyhydroxide adsorbs such molecules due to phosphate ligand exchange and/or electrostatic interactions
Implementation Method 2
aluminum oxyhydroxide adsorbs such molecules due to phosphate ligand exchange and/or electrostatic interactions
Implementation Method 3
aluminum oxyhydroxide adsorbs such molecules due to phosphate ligand exchange and/or electrostatic interactions
Data Source
AI summary
Stable aqueous formulations of adjuvant comprising a TLR7/8 agonist or a TLR4 agonist with a helper lipid that are adsorbed to alum are provided. Compositions and methods of using the formulations for stimulating an immune response are also provided.